Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
| Revenue (TTM) | $1.77M |
| Gross Profit (TTM) | $-61.05M |
| EBITDA | $-88.90M |
| Operating Margin | -33973.00% |
| Return on Equity | -7029.00% |
| Return on Assets | -16.40% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $-5.19 |
| Price-to-Book | 31.26 |
| Price-to-Sales (TTM) | 111.73 |
| EV/Revenue | 52.07 |
| EV/EBITDA | 1.77 |
| Quarterly Earnings Growth (YoY) | -7.40% |
| Quarterly Revenue Growth (YoY) | -92.90% |
| Shares Outstanding | $29.38M |
| Float | $9.57M |
| % Insiders | 53.68% |
| % Institutions | 24.55% |
Volatility is currently expanding